Abstract
The COVID-19 pandemic has resulted in many therapies, of which many are repurposed and used for other diseases in the last decade such in Influenza and Ebola. We intend to provide a robust foundation for cardiovascular outcomes of the therapies to better understand the rationale for the clinical trials that were conducted during the COVID-19 pandemic, and better understand the steps moving forward should the repurposing provide clinical benefit in pandemic situations. With this state-of-the-art review, we aim to improve the understanding of the cardiovascular involvement of the therapies prior to, during, and after the COVID-19 pandemic to provide meaningful findings to the cardiovascular specialists and clinical trials for therapies, moving on from the period of pandemic urgency.
Recommended Citation
Sarfraz, Azza; Sarfraz, Zouina; Bano, Shehar; Sarfraz, Muzna; Jaan, Ali; Minhas, Amna; Razzack, Aminah Abdul; Patel, Gaurav; KC, Manish; Makkar, Sarabjot Singh; Garimella, Radhika; Pandav, Krunal; Almonte, Jose; Paul, Trissa; Almonte, Tahlianna; Jimenez, Lissandra; Pantoga, Juan C; El Mazboudi, Nada; Yatzkan, George; Michel, George; and Michel, Jack
(2024)
"Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review,"
Journal of Community Hospital Internal Medicine Perspectives: Vol. 14:
Iss.
2, Article 8.
DOI: 10.55729/2000-9666.1308
Available at:
https://scholarlycommons.gbmc.org/jchimp/vol14/iss2/8